

8. Literatur

Aimone, L.D., Yaksh, T.L., 1989. Opioid modulation of capsaicin-evoked release of substance P from rat spinal cord in vivo. *Peptides* 10, 1127-1131.

Akiyama, H., Barger, S., Barnum, S., et al., 2000. Inflammation and Alzheimer's disease. *Neurobiol Aging* 21, 383-421.

Aliakbari, J., Sreedharan, S.P., Turck, C.W., Goetzl, E.J., 1987. Selective localization of vasoactive intestinal peptide and substance P in human eosinophils. *Biochem Biophys Res Commun* 148, 1440-1445.

Almay, B.G., Johansson, F., Von Knorring, L., Le Greves, P., Terenius, L., 1988. Substance P in CSF of patients with chronic pain syndromes. *Pain* 33, 3-9.

Almay, B.G., Johansson, F., von Knorring, L., Sakurada, T., Terenius, L., 1985. Long-term high frequency transcutaneous electrical nerve stimulation (hi-TNS) in chronic pain. Clinical response and effects on CSF-endorphins, monoamine metabolites, substance P-like immunoreactivity (SPLI) and pain measures. *J Psychosom Res* 29, 247-257.

Anichini, M., Cesaretti, S., Lepori, M. et al., 1997. Substance P in the serum of patients with rheumatoid arthritis. *Rev Rhum Engl Ed* 64, 18-21.

Assicot, M., Gendrel, D., Carsin, H., Raymond, J., Guilbaud, J., Bohuon, C., 1993. High serum procalcitonin concentrations in patients with sepsis and infection. *Lancet* 341, 515-518.

Barelli, H., Fox-Threlkeld, J.E., Dive, V., et al., 1994. Role of endopeptidase 3.4.24.16 in the catabolism of neurotensin, in vivo, in the vascularly perfused dog ileum. *Br J Pharmacol* 112, 127-132.

Barker, R., Larner, A., 1992. Substance P and multiple sclerosis. *Med Hypotheses* 37, 40-43.

Bartho, L., Maggi, C.A., Wilhelm, M., Patacchini, R., 1994. Tachykinin NK1 and NK2 receptors mediate atropine-resistant ileal circular muscle contractions evoked by capsaicin. *Eur J Pharmacol* 259, 187-193.

Beal, M.F., Mazurek, M.F., 1987. Substance P-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex. *Neurology* 37, 1205-1209.

Beer, S., Weighardt, H., Emmanuilidis, K., Harzenetter, M.D., et al., 2002. Systemic neuropeptide levels as predictive indicators for lethal outcome in patients with postoperative sepsis. *Crit Care Med* 30, 1794-1798.

Behar, O., Ovadia, H., Polakiewicz, R.D., Rosen, H., 1994. Lipopolysaccharide induces pro-enkephalin gene expression in rat lymph nodes and adrenal glands. *Endocrinology* 134, 475-481.

Beinfeld, M.C., 1998. Prohormone and proneuropeptide processing. Recent progress and future challenges. *Endocrine* 8, 1-5.

Berger, H., Fechner, K., Albrecht, E., Niedrich, H., 1979. Substance P: in vitro inactivation by rat brain fractions and human plasma. *Biochem Pharmacol* 28, 3173-3180.

Bergstrom, M., Theodorsson, E., Norheim, I., Oberg, K., 1995. Immunoreactive tachykinins in 24-h collections of urine from patients with carcinoid tumours: characterization and correlation with plasma concentrations. *Scand J Clin Lab Invest* 55, 679-689.

Bickel, H., 2000. Dementia syndrome and Alzheimer disease: an assessment of morbidity and annual incidence in Germany. *Gesundheitswesen* 62, 211-218.

Billingsley, M.L., Kincaid, R.L., 1997. Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. *Biochem J* 323 (Pt 3), 577-591.

Birnbaum, R.S., Mahoney, W.C., Burns, D.M., et al. 1984. Identification of procalcitonin in a rat medullary thyroid carcinoma cell line. *J Biol Chem* 259, 2870-2874.

- Blennow, K., 2004. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. *NeuroRx* 1, 213-225.
- Blennow, K., Vanmechelen, E., Hampel, H., 2001. CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. *Mol Neurobiol* 24, 87-97.
- Boarder, M.R., Erdelyi, E., Barchas, J.D., 1982. Opioid peptides in human plasma: evidence for multiple forms. *J Clin Endocrinol Metab* 54, 715-720.
- Bondy, B., Baghai, T.C., Minov, C., et al., 2003. Substance P serum levels are increased in major depression: preliminary results. *Biol Psychiatry* 53, 538-542.
- Bouras, C., Vallet, P.G., Hof, P.R., Charnay, Y., Golaz, J., Constantinidis, J., 1990. Substance P immunoreactivity in Alzheimer disease: a study in cases presenting symmetric or asymmetric cortical atrophy. *Alzheimer Dis Assoc Disord* 4, 24-34.
- Bourgoin, S., Rostaing-Rigattieri, S., Nguyen, J.P., et al., 1999. Opposite changes in dopamine metabolites and met-enkephalin levels in the ventricular CSF of patients subjected to thalamic electrical stimulation. *Clin Neuropharmacol* 22, 231-238.
- Boyles, J.K., Pitas, R.E., Wilson, E., Mahley, R.W., Taylor, J.M., 1985. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. *J Clin Invest* 76, 1501-1513.
- Braithwaite, S., 2000. Procalcitonin: new insights on regulation and origin. *Crit Care Med* 28, 586-588.
- Brunkhorst, F.M., Heinz, U., Forycki, Z.F., 1998. Kinetics of procalcitonin in iatrogenic sepsis. *Intensive Care Med* 24, 888-889.
- Bruno, G., Tega, F., Bruno, A. et al., 2003. The role of substance P in cerebral ischemia. *Int J Immunopathol Pharmacol* 16, 67-72.

- Bruscoli, M., Lovestone, S., 2004. Is MCI really just early dementia? A systematic review of conversion studies. *Int Psychogeriatr* 16, 129-140.
- Buee, L., Bussiere, T., Buee-Scherrer, V., Delacourte, A., Hof, P.R., 2000. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. *Brain Res Brain Res Rev* 33, 95-130.
- Bush, J.A., Mastro, A.M., Kraemer, W.J., 2006. Proenkephalin peptide F immunoreactivity in different circulatory biocompartments after exercise. *Peptides* 27, 1498-1506.
- Cailes, J., Winter, S., du Bois, R.M., Evans, T.W., 1998. Defective endothelially mediated pulmonary vasodilation in systemic sclerosis. *Chest* 114, 178-184.
- Calhoun, K., Toth-Fejel, S., Cheek, J., Pommier, R., 2003. Serum peptide profiles in patients with carcinoid tumors. *Am J Surg* 186, 28-31.
- Carter, M.S., Krause, J.E., 1990. Structure, expression, and some regulatory mechanisms of the rat preprotachykinin gene encoding substance P, neurokinin A, neuropeptide K, and neuropeptide gamma. *J Neurosci* 10, 2203-2214.
- Chadzinska, M., Maj, M., Scislowska-Czarnecka, A., Przewlocka, B., Plytycz, B., 2001. Expression of proenkephalin (PENK) mRNA in inflammatory leukocytes during experimental peritonitis in Swiss mice. *Pol J Pharmacol* 53, 715-718.
- Christ-Crain, M., Stoeckli, R., Ernst, A., et al., 2006. Effect of gastric bypass and gastric banding on proneurotensin levels in morbidly obese patients. *J Clin Endocrinol Metab* 91, 3544-3547.
- Ciesla, A., Pierzchala-Koziec, K., Mach, T., Garlicki, A., Bociaga-Jasik, M., 2005. [Met-enkephalin in the cerebrospinal fluid as an indicator of central nervous system injury in meningitis and encephalitis]. *Pol Merkur Lekarski* 18, 549-551.
- Conlon, J.M., Sheehan, L., 1983. Conversion of substance P to C-terminal fragments in human plasma. *Regul Pept* 7, 335-345.

Consensus Report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. 1998 *Neurobiol Aging* 19, 109-116.

Corbally, N., Powell, D., Tipton, K.F., 1990. The binding of endogenous and exogenous substance-P in human plasma. *Biochem Pharmacol* 39, 1161-1166.

Corder, E.H., Saunders, A.M., Strittmatter, et al., 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* 261, 921-923.

Cramer, H., Schaudt, D., Rissler, K., et al., 1985. Somatostatin-like immunoreactivity and substance-P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multi-infarct syndrome and communicating hydrocephalus. *J Neurol* 232, 346-351.

Crook, T., Bahar, H., Sudilovsky, A., 1987. Age-associated memory impairment: diagnostic criteria and treatment strategies. *Int J Neurol* 21-22, 73-82.

Cummings, J.L., Vinters, H.V., Cole, G.M., Khachaturian, Z.S., 1998. Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. *Neurology* 51, S2-17; discussion S65-17.

Davis, R.E., Miller, S., Herrstadt, C., et al., 1997. Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. *Proc Natl Acad Sci U S A* 94, 4526-4531.

de Lourdes Figuerola, M., Leston, J., Barontini, M., 1996. Plasma met-enkephalin levels: its relationship with age and type of headache. *Arch Gerontol Geriatr* 22, 137-143.

de Wied, D., 1997. Neuropeptides in learning and memory processes. *Behav Brain Res* 83, 83-90.

Debeljuk, L., Lasaga, M., 1999. Modulation of the hypothalamo-pituitary-gonadal axis and the pineal gland by neurokinin A, neuropeptide K and neuropeptide gamma. *Peptides* 20, 285-299.

Deuschle, M., Sander, P., Herpfer, I., Fiebich, B.L., Heuser, I., Lieb, K., 2005. Substance P in serum and cerebrospinal fluid of depressed patients: no effect of antidepressant treatment. *Psychiatry Res* 136, 1-6.

Devi, L., 1991. Consensus sequence for processing of peptide precursors at monobasic sites. *FEBS Lett* 280, 189-194.

Drolet, G., Dumont, E.C., Gosselin, I., et al., 2001. Role of endogenous opioid system in the regulation of the stress response. *Prog Neuropsychopharmacol Biol Psychiatry* 25, 729-741.

Drouet, B., Pincon-Raymond, M., Chambaz, J., Pillot, T., 2000. Molecular basis of Alzheimer's disease. *Cell Mol Life Sci* 57, 705-715.

Eipper, B.A., Milgram, S.L., Husten, E.J., Yun, H.Y., Mains, R.E., 1993. Peptidylglycine alpha-amidating monooxygenase: a multifunctional protein with catalytic, processing, and routing domains. *Protein Sci* 2, 489-497.

Ernst, A., Hellmich, S., Bergmann, A., 2006. Proneurotensin 1-117, a stable neurotensin precursor fragment identified in human circulation. *Peptides* 27, 1787-1793.

Farrer, L.A., Cupples, L.A., Haines, J.L., et al., 1997. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *Jama* 278, 1349-1356.

Feany, M.B., 1996. Neuropeptide modulation of learning and memory processes. *Rev Neurosci* 7, 151-164.

Ferri, C.P., Prince, M., Brayne, C., et al., 2005. Global prevalence of dementia: a Delphi consensus study. *Lancet* 366, 2112-2117.

Figini, M., Emanuelli, C., Bertrand, C., Javdan, P., Geppetti, P., 1996. Evidence that tachykinins relax the guinea-pig trachea via nitric oxide release and by stimulation of a septide-insensitive NK1 receptor. *Br J Pharmacol* 117, 1270-1276.

Figuerola, M.L., Vindrola, O., Barontini, M.B., Leston, J.A., 1990. Increase in plasma methionine-enkephalin levels during the pain attack in episodic cluster headache. *Cephalalgia* 10, 251-257.

Folstein, M.F., Folstein, S.E., McHugh, P.R., 1975. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 12, 189-198.

Frank, R.A., Galasko, D., Hampel, H., et al., 2003. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. *Neurobiol Aging* 24, 521-536.

Fuchsberger, T., Padberg, F., Faltraco, F., Moller, H.J., Hampel, H., 2002. [Starting Alzheimer therapy in early stages whenever possible. Activities of daily living remain intact longer]. *MMW Fortschr Med* 144, 36-39.

Geula, C., Mesulam, M.M., 1996. Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimer's disease. *Cereb Cortex* 6, 165-177.

Giurgea, C., 1973. The "nootropic" approach to the pharmacology of the integrative activity of the brain. *Cond Reflex* 8, 108-115.

Goedert, M., Spillantini, M.G., Potier, M.C., Ulrich, J., Crowther, R.A., 1989. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. *Embo J* 8, 393-399.

Gottfries, C.G., Frederiksen, S.O., Heilig, M., 1995. Neuropeptides and Alzheimer's disease. *Eur Neuropsychopharmacol* 5, 491-500.

Goumon, Y., Strub, J.M., Moniatte, M., et al., 1996. The C-terminal bisphosphorylated proenkephalin-A-(209-237)-peptide from adrenal medullary chromaffin granules possesses antibacterial activity. *Eur J Biochem* 235, 516-525.

Gouras, G.K., 2001. Current theories for the molecular and cellular pathogenesis of Alzheimers disease. *Expert Rev Mol Med* 2001, 1-11.

Govoni, S., Pasinetti, G., Bianchi, A., Gadola, M., Trabucchi, M., 1987. Heavy drinking decreases plasma met-enkephalin concentrations. *Alcohol Drug Res* 7, 93-98.

Hampel, H., Muller-Spahn, F., Berger, C., et al., 1995. Evidence of blood-cerebrospinal fluid-barrier impairment in a subgroup of patients with dementia of the Alzheimer type and major depression: a possible indicator for immunoactivation. *Dementia* 6, 348-354.

Hampel, H., Buerger, K., Zinkowski, R., et al., 2004. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. *Arch Gen Psychiatry* 61, 95-102.

Han, J.S., Chen, X.H., Sun, S.L., et al., 1991. Effect of low- and high-frequency TENS on Met-enkephalin-Arg-Phe and dynorphin A immunoreactivity in human lumbar CSF. *Pain* 47, 295-298.

Han, Y.Y., Carcillo, J.A., Ruppel, R.A., et al., 2002. Cerebrospinal fluid procalcitonin and severe traumatic brain injury in children. *Pediatr Crit Care Med* 3, 39-44.

Hansen, L.A., DeTeresa, R., Davies, P., Terry, R.D., 1988. Neocortical morphometry, lesion counts, and choline acetyltransferase levels in the age spectrum of Alzheimer's disease. *Neurology* 38, 48-54.

Harajiri, S., Wood, G., Desiderio, D.M., 1992. Analysis of proenkephalin A, proopiomelanocortin and protachykinin neuropeptides in human lumbar cerebrospinal fluid by reversed-phase high-performance liquid chromatography, radioimmunoassay and enzymolysis. *J Chromatogr* 575, 213-222.

Harrison, S., Geppetti, P., 2001. Substance p. *Int J Biochem Cell Biol* 33, 555-576.

Hasenohrl, R.U., Souza-Silva, M.A., Nikolaus, S., et al., 2000. Substance P and its role in neural mechanisms governing learning, anxiety and functional recovery. *Neuropeptides* 34, 272-280.

Hillyard, C.J., Myers, C., Abeyasekera, G., Stevvensverson, J.C., Craig, R.K., MacIntyre, I., 1983. Katalcalcin: a new plasma calcium-lowering hormone. *Lancet* 1, 846-848.

Holtzman, D.M., Bales, K.R., Tenkova, T., et al., 2000. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. *Proc Natl Acad Sci U S A* 97, 2892-2897.

Horikawa, S., Takai, T., Toyosato, M., et al., 1983. Isolation and structural organization of the human preproenkephalin B gene. *Nature* 306, 611-614.

Hunt, P.J., Yandle, T.G., Nicholls, M.G., Richards, A.M., Espiner, E.A., 1995. The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. *Biochem Biophys Res Commun* 214, 1175-1183.

Iadarola, M.J., Mouradian, M.M., 1989. Decrease in a proenkephalin peptide in cerebrospinal fluid in Huntington's disease and progressive supranuclear palsy. *Brain Res* 479, 397-401.

Itoh, N., Arai, H., Urakami, K., et al., 2001. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. *Ann Neurol* 50, 150-156.

Jereb, M., Muzlovic, I., Hojker, S., Strle, F., 2001. Predictive value of serum and cerebrospinal fluid procalcitonin levels for the diagnosis of bacterial meningitis. *Infection* 29, 209-212.

Jia, J.P., Meng, R., Sun, Y.X., Sun, W.J., Ji, X.M., Jia, L.F., 2005. Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia. *Neurosci Lett* 383, 12-16.

Kage, R., Thim, L., Creutzfeldt, W., Conlon, J.M., 1988. Post-translational processing of preprotachykinins. Isolation of protachykinin-(1-37)-peptide from human adrenal-medullary pheochromocytoma tissue. *Biochem J* 253, 203-207.

Kamboh, M.I., Sanghera, D.K., Ferrell, R.E., DeKosky, S.T., 1995. APOE*4-associated Alzheimer's disease risk is modified by alpha 1-antichymotrypsin polymorphism. *Nat Genet* 10, 486-488.

Kamphuis, S., Eriksson, F., Kavelaars, A., et al., 1998. Role of endogenous pro-enkephalin A-derived peptides in human T cell proliferation and monocyte IL-6 production. *J Neuroimmunol* 84, 53-60.

Kapaki, E., Kilidireas, K., Paraskevas, G.P., Michalopoulou, M., Patsouris, E., 2001. Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease? *J Neurol Neurosurg Psychiatry* 71, 401-403.

Katsuse, O., Iseki, E., Kosaka, K., 2003. Immunohistochemical study of the expression of cytokines and nitric oxide synthases in brains of patients with dementia with Lewy bodies. *Neuropathology* 23, 9-15.

Kepa, L., Oczko-Grzesik, B., Bledowski, D., 2005. [Procalcitonin (PCT) concentration in cerebrospinal fluid and plasma of patients with purulent and lymphocytic meningoencephalitis--own observations]. *Przegl Epidemiol* 59, 703-709.

Kidd, M., 1963. Paired helical filaments in electron microscopy of Alzheimer's disease. *Nature* 197, 192-193.

Kiriyama, Y., Nomura, Y., Tokumitsu, Y., 2002. Calcitonin gene expression induced by lipopolysaccharide in the rat pituitary. *Am J Physiol Endocrinol Metab* 282, E1380-1384.

Kischka, U., Ettl, T., 2005. Vaskuläre Demenzen - Wie sie von degenerativen Demenzen abgegrenzt werden. pp 13-17.

Kobari, M., Ishihara, N., Yunoki, K., 1988. Increase of plasma methionine-enkephalin levels in patients at the acute stage of cerebral infarction. *Neurol Res* 10, 120-122.

Kohnken, R., Buerger, K., Zinkowski, R., et al., 2000. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. *Neurosci Lett* 287, 187-190.

Kojima, K., Kilpatrick, D.L., Stern, A.S., Jones, B.N., Udenfriend, S., 1982. Proenkephalin: a general pathway for enkephalin biosynthesis in animal tissues. *Arch Biochem Biophys* 215, 638-643.

Korshunova, T.S., Koli, G.A., Larskii, E.G., Ivanova-Smolenskaia, I.A., Markova, E.D., 1984. [Endogenous morphines in chronic progressive diseases of the central nervous system]. *Zh Nevropatol Psikhiatr Im S S Korsakova* 84, 1061-1064.

Kosaka, K., Yoshimura, M., Ikeda, K., et al., 1984. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree-- a new disease? *Clin Neuropathol* 3, 185-192.

Kowalska, K., Carr, D.B., Lipkowski, A.W., 2002. Direct antimicrobial properties of substance P. *Life Sci* 71, 747-750.

Kunt, T., Forst, T., Schmidt, S., et al., 2000. Serum levels of substance P are decreased in patients with type 1 diabetes. *Exp Clin Endocrinol Diabetes* 108, 164-167.

Lai, J.P., Douglas, S.D., Rappaport, E., et al., 1998. Identification of a delta isoform of prepro-tachykinin mRNA in human mononuclear phagocytes and lymphocytes. *J Neuroimmunol* 91, 121-128.

Langemark, M., Bach, F.W., Ekman, R., Olesen, J., 1995. Increased cerebrospinal fluid Met-enkephalin immunoreactivity in patients with chronic tension-type headache. *Pain* 63, 103-107.

Leitlinien für Diagnostik und Therapie in der Neurologie. 2005. Thieme Verlag.

Levy-Lahad, E., Wasco, W., Poorkaj, P., et al., 1995. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. *Science* 269, 973-977.

Linnik, M.D., Moskowitz, M.A., 1989. Identification of immunoreactive substance P in human and other mammalian endothelial cells. *Peptides* 10, 957-962.

- Liu, D.X., Dass, C., Wood, G., Desiderio, D.M., 1990. Opioid and tachykinin peptides, and their precursors and precursor-processing enzymes, in human cerebrospinal fluid. *J Chromatogr* 500, 395-412.
- Lockinger, A., Koberle, D., Konig, P.S., et al., 2004. Neuropeptide chronomics in clinically healthy young adults: circadian and circadian patterns. *Peptides* 25, 533-542.
- Lopez, O.L., Litvan, I., Catt, K.E., et al., 1999. Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. *Neurology* 53, 1292-1299.
- Mackenzie, I.R., 2000. Activated microglia in dementia with Lewy bodies. *Neurology* 55, 132-134.
- Maggi, C.A., 1995. Tachykinins and calcitonin gene-related peptide (CGRP) as co-transmitters released from peripheral endings of sensory nerves. *Prog Neurobiol* 45, 1-98.
- Maggi, C.A., 1997. The effects of tachykinins on inflammatory and immune cells. *Regul Pept* 70, 75-90.
- Mahley, R.W., 1988. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. *Science* 240, 622-630.
- Martinez, M., Frank, A., Hernanz, A., 1993. Relationship of interleukin-1 beta and beta 2-microglobulin with neuropeptides in cerebrospinal fluid of patients with dementia of the Alzheimer type. *J Neuroimmunol* 48, 235-240.
- Maruna, P., Nedelnikova, K., Gurlich, R., 2000. Physiology and genetics of procalcitonin. *Physiol Res* 49 Suppl 1, S57-61.
- Mateo, Z., Napier, L., Gaugl, J.F., Barron, B.A., Caffrey, J.L., 1995. Hemorrhage alters plasma and cardiac enkephalins and catecholamines in anesthetized dogs. *Am J Physiol* 269, H2082-2089.

Matsuishi, T., Nagamitsu, S., Shoji, H., et al., 1999. Increased cerebrospinal fluid levels of substance P in patients with amyotrophic lateral sclerosis. Short communication. *J Neural Transm* 106, 943-948.

McArthur, J., Hill, J., Paech, M.J., Dodd, P.H., Bennett, E.J., Holden, J., 2005. Cerebrospinal fluid and serum concentrations of beta-trace protein during pregnancy. *Anaesthesia* 60, 163-167.

McKeith, I., Mintzer, J., Aarsland, D., et al., 2004. Dementia with Lewy bodies. *Lancet Neurol* 3, 19-28.

McKeith, I.G., Galasko, D., Kosaka, K., et al., 1996. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. *Neurology* 47, 1113-1124.

McKhann, G., Drachman, D., Folstein, M. et al., 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology* 34, 939-944.

McKhann, G.M., Albert, M.S., Grossman, M., Miller, B., Dickson, D., Trojanowski, J.Q., 2001. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. *Arch Neurol* 58, 1803-1809.

Meisner, M., Lohs, T., Huettemann, E., Schmidt, J., Hueller, M., Reinhart, K., 2001. The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function. *Eur J Anaesthesiol* 18, 79-87.

Melani, F., Rubenstein, A.H., Oyer, P.E., Steiner, D.F., 1970. Identification of proinsulin and C-peptide in human serum by a specific immunoassay. *Proc Natl Acad Sci U S A* 67, 148-155.

Meyer, M.R., Tschanz, J.T., Norton, M.C., et al., 1998. APOE genotype predicts when--not whether--one is predisposed to develop Alzheimer disease. *Nat Genet* 19, 321-322.

Miller, D.L., Papayannopoulos, I.A., Styles, J., et al., 1993. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. *Arch Biochem Biophys* 301, 41-52.

Minghetti, L., 2005. Role of inflammation in neurodegenerative diseases. *Curr Opin Neurol* 18, 315-321.

Moise P., Schwarzinger M., Um M.-Y. and the Dementia Experts' Group, 2004. Dementia Care in 9 OECD countries: A comparative analysis. OECD Health Working Papers No. 13.

Molinuevo, J.L., Llado, A., Rami, L., 2005. Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias. *Am J Alzheimers Dis Other Demen* 20, 77-85.

Morgenthaler, N.G., Struck, J., Alonso, C., Bergmann, A., 2005. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. *Clin Chem* 51, 1823-1829.

Morgenthaler, N.G., Struck, J., Alonso, C., Bergmann, A., 2006. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. *Clin Chem* 52, 112-119.

Morgenthaler, N.G., Struck, J., Chancerelle, Y., et al., 2003. Production of procalcitonin (PCT) in non-thyroidal tissue after LPS injection. *Horm Metab Res* 35, 290-295.

Morgenthaler, N.G., Struck, J., Fischer-Schulz, C., Bergmann, A., 2002a. Sensitive immunoluminometric assay for the detection of procalcitonin. *Clin Chem* 48, 788-790.

Morgenthaler, N.G., Struck, J., Fischer-Schulz, C., Seidel-Mueller, E., Beier, W., Bergmann, A., 2002b. Detection of procalcitonin (PCT) in healthy controls and patients with local infection by a sensitive ILMA. *Clin Lab* 48, 263-270.

Morgenthaler, N.G., Struck, J., Thomas, B., Bergmann, A., 2004. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. *Clin Chem* 50, 234-236.

Mosnaim, A.D., Puente, J., Saavedra, R., Diamond, S., Wolf, M.E., 2003. In vitro human plasma leucine(5)-enkephalin degradation is inhibited by a select number of drugs with the phenothiazine molecule in their chemical structure. *Pharmacology* 67, 6-13.

Mosnaim, A.D., Puente, J., Wolf, M.E., et al., 1988. Studies of the in vitro human plasma degradation of methionine-enkephalin. *Gen Pharmacol* 19, 729-733.

Muhlbauer, M., Metcalf, J.C., Jr., Robertson, J.T., Fridland, G., Desiderio, D.M., 1986. Opioid peptides in the cerebrospinal fluid of Alzheimer patients. *Biomed Chromatogr* 1, 155-158.

Muller, B., White, J.C., Nylen, E.S. et al., 2001. Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. *J Clin Endocrinol Metab* 86, 396-404.

Muller, W.E., Mutschler, E., Riederer, P., 1995. Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia. *Pharmacopsychiatry* 28, 113-124.

Munoz, D.G., Dickson, D.W., Bergeron, C., et al., 2003. The neuropathology and biochemistry of frontotemporal dementia. *Ann Neurol* 54 Suppl 5, S24-28.

Noda, M., Teranishi, Y., Takahashi, H., et al., 1982. Isolation and structural organization of the human preproenkephalin gene. *Nature* 297, 431-434.

Nyberg, F., 2004. Opioid peptides in cerebrospinal fluid-methods for analysis and their significance in the clinical perspective. *Front Biosci* 9, 3510-3525.

Nyberg, F., Nylander, I., Terenius, L., 1986. Enkephalin-containing polypeptides in human cerebrospinal fluid. *Brain Res* 371, 278-286.

Nyberg, F., Terenius, L., 1985. Identification of high molecular weight enkephalin precursor forms in human cerebrospinal fluid. *Neuropeptides* 5, 537-540.

O'Connor, E., Venkatesh, B., Lipman, J., Mashongonyika, C., Hall, J., 2001. Procalcitonin in critical illness. *Crit Care Resusc* 3, 236-243.

Ojeda, M.L., Ambrosiani, J., Tavares, E., Maldonado, R., Minano, F.J., 2006. Identification and localization of procalcitonin-like immunoreactivity in the rat hypothalamus. *Neurosci Lett* 408, 40-45.

Otto, M., Esselmann, H., Schulz-Shaeffer, W., et al., 2000. Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. *Neurology* 54, 1099-1102.

Papassotiriou, J., Morgenthaler, N.G., Struck, J., Alonso, C., Bergmann, A., 2006. Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma. *Clin Chem* 52, 1144-1151.

Papassotiropoulos, A., Bagli, M., Jessen, F., et al., 1999. A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease. *Ann Neurol* 45, 666-668.

Parris, W.G., Tanzer, F.S., Fridland, G.H., Harris, E.F., Killmar, J., Desiderio, D.M., 1989. Effects of orthodontic force on methionine enkephalin and substance P concentrations in human pulpal tissue. *Am J Orthod Dentofacial Orthop* 95, 479-489.

Pascual, D.W., Bost, K.L., 1990. Substance P production by P388D1 macrophages: a possible autocrine function for this neuropeptide. *Immunology* 71, 52-56.

Perone, M.J., Castro, M.G., 1997. Prohormone and proneuropeptide synthesis and secretion. *Histol Histopathol* 12, 1179-1188.

Pezzoli, G., Panerai, A.E., Di Giulio, A., Longo, A., Passerini, D., Carezzi, A., 1984. Methionine-enkephalin, substance P, and homovanillic acid in the CSF of parkinsonian patients. *Neurology* 34, 516-519.

Pio, R., Martinez, A., Unsworth, E.J., et al., 2001. Complement factor H is a serum-binding protein for adrenomedullin, and the resulting complex modulates the bioactivities of both partners. *J Biol Chem* 276, 12292-12300.

Pittius, C.W., Seizinger, B.R., Mehraein, P., Pasi, A., Herz, A., 1983. Proenkephalin-A-derived peptides are present in human brain. *Life Sci* 33 Suppl 1, 41-44.

Plotnikoff, N.P., Faith, R.E., Murgo, A.J., Herberman, R.B., Good, R.A., 1997. Methionine enkephalin: a new cytokine--human studies. *Clin Immunol Immunopathol* 82, 93-101.

Possenti, R., De Marco, V., Cherubini, O., Roda, L.G., 1983. Enkephalin-binding systems in human plasma. *Neurochem Res* 8, 423-432.

Preibisz, J.J., Sealey, J.E., Laragh, J.H., Cody, R.J., Weksler, B.B., 1983. Plasma and platelet vasopressin in essential hypertension and congestive heart failure. *Hypertension* 5, 1129-138.

Przewlocki, R., Przewlocka, B., 2001. Opioids in chronic pain. *Eur J Pharmacol* 429, 79-91.

Qureshi, G.A., Baig, S.M., Parvez, S.H., 2000. Variation in cerebrospinal fluid levels of neuropeptide Y, cholecystokinin and substance P in patients with neurological disorders. *Neuroendocrinol Lett* 21, 409-416.

Rameshwar, P., Ganea, D., Gascon, P., 1993. In vitro stimulatory effect of substance P on hematopoiesis. *Blood* 81, 391-398.

Reiber, H., 1998. Cerebrospinal fluid--physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. *Mult Scler* 4, 99-107.

Reiber, H., Peter, J.B., 2001. Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. *J Neurol Sci* 184, 101-122.

Reiber, H., 2003a. Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics. *Restor Neurol Neurosci* 21, 79-96.

Reiber, H., Thompson, E.J., Grimsley, G., et al. 2003b. Quality assurance for cerebrospinal fluid protein analysis: international consensus by an Internet-based group discussion. *Clin Chem Lab Med* 41, 331-337.

Reiber, H., Walther, K., Althaus, H., 2003c. Beta-trace protein as sensitive marker for CSF rhinorrhea and CSF otorrhea. *Acta Neurol Scand* 108, 359-362.

Reiber, H., 2005. Liquordiagnostik. In: *Labor und Diagnose - Indikationen und Bewertung von Laborbefunden für die medizinische Diagnostik*. Hrsg.: Thomas, L. TH-Books. 6. Auflage, 1743-1784.

Rentzos, M., Zoga, M., Paraskevas, G.P., et al., 2006. IL-15 is elevated in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. *J Geriatr Psychiatry Neurol* 19, 114-117.

Richfield, E.K., Vonsattel, J.P., MacDonald, M.E., Sun, Z., Deng, Y.P., Reiner, A., 2002. Selective loss of striatal preprotachykinin neurons in a phenocopy of Huntington's disease. *Mov Disord* 17, 327-332.

Ronald, A., Stimson, W.H., 1998. The evolution of immunoassay technology. *Parasitology* 117 Suppl, S13-27.

Rosen, H., Polakiewicz, R.D., Benzakine, S., Bar-Shavit, Z., 1991. Proenkephalin A in bone-derived cells. *Proc Natl Acad Sci U S A* 88, 3705-3709.

Rosler, N., Wichart, I., Jellinger, K.A., 2001. Ex vivo lumbar and post mortem ventricular cerebrospinal fluid substance P-immunoreactivity in Alzheimer's disease patients. *Neurosci Lett* 299, 117-120.

Russell, I.J., 1998. Neurochemical pathogenesis of fibromyalgia. *Z Rheumatol* 57 Suppl 2, 63-66.

Salzet, M., Tasiemski, A., 2001. Involvement of pro-enkephalin-derived peptides in immunity. *Dev Comp Immunol* 25, 177-185.

Samuelsson, H., Ekman, R., Hedner, T., 1993. CSF neuropeptides in cancer pain: effects of spinal opioid therapy. *Acta Anaesthesiol Scand* 37, 502-508.

Schellenberg, G.D., Payami, H., Wijsman, E.M., et al., 1993. Chromosome 14 and late-onset familial Alzheimer disease (FAD). *Am J Hum Genet* 53, 619-628.

Schultheis, G., Martinez, J.L., Jr., 1992. Peripheral modulation of learning and memory: enkephalins as a model system. *Psychopharmacology (Berl)* 109, 347-364.

Schwartz, T.W., 1986. The processing of peptide precursors. 'Proline-directed arginyl cleavage' and other monobasic processing mechanisms. *FEBS Lett* 200, 1-10.

Shen, Y., Li, R., 1995. The role of neuropeptides in learning and memory: possible mechanisms. *Med Hypotheses* 45, 529-538.

Sherrington, R., Rogae, E.I., Liang, Y., et al., 1995. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. *Nature* 375, 754-760.

Sjogren, M., Davidsson, P., Tullberg, M., et al., 2001. Both total and phosphorylated tau are increased in Alzheimer's disease. *J Neurol Neurosurg Psychiatry* 70, 624-630.

Sjogren, M., Davidsson, P., Wallin, A., et al., 2002. Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. *Dement Geriatr Cogn Disord* 13, 112-118.

Sjogren, M., Folkesson, S., Blennow, K., Tarkowski, E., 2004. Increased intrathecal inflammatory activity in frontotemporal dementia: pathophysiological implications. *J Neurol Neurosurg Psychiatry* 75, 1107-1111.

Snider, R.H., Jr., Nylén, E.S., Becker, K.L., 1997. Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization. *J Investig Med* 45, 552-560.

Spillantini, M.G., Goedert, M., 2000. Tau mutations in familial frontotemporal dementia. *Brain* 123 (Pt 5), 857-859.

Spivey, J.R., Jorgensen, R.A., Gores, G.J., Lindor, K.D., 1994. Methionine-enkephalin concentrations correlate with stage of disease but not pruritus in patients with primary biliary cirrhosis. *Am J Gastroenterol* 89, 2028-2032.

Spruce, B.A., Curtis, R., Wilkin, G.P., Glover, D.M., 1990. A neuropeptide precursor in cerebellum: proenkephalin exists in subpopulations of both neurons and astrocytes. *Embo J* 9, 1787-1795.

Stachura, Z., Kowalski, J., Obuchowicz, E., Huzarska, M., Herman, Z.S., 1997. Concentration of enkephalins in cerebrospinal fluid of patients after severe head injury. *Neuropeptides* 31, 78-81.

Stark, M., Danielsson, O., Griffiths, W.J., Jornvall, H., Johansson, J., 2001. Peptide repertoire of human cerebrospinal fluid: novel proteolytic fragments of neuroendocrine proteins. *J Chromatogr B Biomed Sci Appl* 754, 357-367.

Stern, A.S., Jones, B.N., Shively, J.E., Stein, S., Udenfriend, S., 1981. Two adrenal opioid polypeptides: proposed intermediates in the processing of proenkephalin. *Proc Natl Acad Sci U S A* 78, 1962-1966.

Stroud, R.M., Walter, P., 1999. Signal sequence recognition and protein targeting. *Curr Opin Struct Biol* 9, 754-759.

Struck, J., Morgenthaler, N.G., Bergmann, A., 2005a. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. *Peptides* 26, 2500-2504.

Struck, J., Morgenthaler, N.G., Bergmann, A., 2005b. Proteolytic processing pattern of the endothelin-1 precursor in vivo. *Peptides* 26, 2482-2486.

Struck, J., Tao, C., Morgenthaler, N.G., Bergmann, A., 2004. Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients. *Peptides* 25, 1369-1372.

Sulkava, R., Erkinjuntti, T., Laatikainen, T., 1985. CSF beta-endorphin and beta-lipotropin in Alzheimer's disease and multi-infarct dementia. *Neurology* 35, 1057-1058.

Sunderland, T., Berrettini, W.H., Molchan, S.E., et al., 1991. Reduced cerebrospinal fluid dynorphin A1-8 in Alzheimer's disease. *Biol Psychiatry* 30, 81-87.

Terry, R.D., 1963. The Fine Structure of Neurofibrillary Tangles in Alzheimer's Disease. *J Neuropathol Exp Neurol* 22, 629-642.

Thompson E.J. 1988. CSF proteins: a biochemical approach. Elsevier, Amsterdam.

Toresson, G., Brodin, E., Bertilsson, L., 1993. N-terminally extended tachykinins in human cerebrospinal fluid. *Regul Pept* 46, 357-359.

Toresson, G., Brodin, E., de las Carreras, C., Nordin, C., Zachau, A.C., Bertilsson, L., 1994. Quantitation of N-terminally extended tachykinins in cerebrospinal fluid from healthy subjects. *Regul Pept* 50, 185-191.

Toresson, G., Brodin, E., Wahlstrom, A., Bertilsson, L., 1988. Detection of N-terminally extended substance P but not of substance P in human cerebrospinal fluid: quantitation with HPLC-radioimmunoassay. *J Neurochem* 50, 1701-1707.

Trojanowski, J.Q., Shin, R.W., Schmidt, M.L., Lee, V.M., 1995. Relationship between plaques, tangles, and dystrophic processes in Alzheimer's disease. *Neurobiol Aging* 16, 335-340; discussion 341-335.

Tumani, H., Nau, R., Felgenhauer, K., 1998. Beta-trace protein in cerebrospinal fluid: a blood-CSF barrier-related evaluation in neurological diseases. *Ann Neurol* 44, 882-889.

Turner, G.B., Johnston, B.T., McCance, D.R., et al., 2006. Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours. *Gut* 55, 1586-1591.

Vanmechelen, E., Vanderstichele, H., Davidsson, P., et al., 2000. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. *Neurosci Lett* 285, 49-52.

Vindrola, O., Chervin, A., Vitale, M., et al., 1998. Elevated proenkephalin-derived peptide levels in ACTH-producing adenomas: nucleus and cytoplasm localization. *Endocrine* 8, 231-240.

Visser, P.J., Kester, A., Jolles, J., Verhey, F., 2006. Ten-year risk of dementia in subjects with mild cognitive impairment. *Neurology* 67, 1201-1207.

Wada-Isoe, K., Wakutani, Y., Urakami, K., Nakashima, K., 2004. Elevated interleukin-6 levels in cerebrospinal fluid of vascular dementia patients. *Acta Neurol Scand* 110, 124-127.

Warburg, O., Christian, W., 1941. Isolierung und Kristallisation des Gärungsferments Enolase. *Biochemische Zeitung* 310, 384-421.

Weglohner, W., Struck, J., Fischer-Schulz, C., et al., 2001. Isolation and characterization of serum procalcitonin from patients with sepsis. *Peptides* 22, 2099-2103.

Wen, H.L., Lo, C.W., Ho, W.K., 1983. Met-enkephalin level in the cerebrospinal fluid of schizophrenic patients. *Clin Chim Acta* 128, 367-371.

Whang, K.T., Steinwald, P.M., White, J.C., et al., 1998. Serum calcitonin precursors in sepsis and systemic inflammation. *J Clin Endocrinol Metab* 83, 3296-3301.

Wiltfang, J., Lewczuk, P., Riederer, P., et al., 2005. Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. *World J Biol Psychiatry* 6, 69-84.

Zaidi, M., Kerby, J., Huang, C.L., et al., 1991. Divalent cations mimic the inhibitory effect of extracellular ionised calcium on bone resorption by isolated rat osteoclasts: further evidence for a "calcium receptor". *J Cell Physiol* 149, 422-427.

Zhu, X., Robertson, J.T., Sacks, H.S., et al., 1995. Opioid and tachykinin neuropeptides in prolactin-secreting human pituitary adenomas. *Peptides* 16, 1097-1107.

Zubrzycka, M., Janecka, A., 2000. Substance P: transmitter of nociception (Minireview). *Endocr Regul* 34, 195-201.